A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease

BACKGROUND: In Japan, selegiline has been approved for combination therapy with levodopa for Parkinson disease (PD). We conducted a trial of selegiline monotherapy for early PD. METHODS: In this 12-week controlled phase III trial, a total of 292 subjects were randomized to receive placebo (n = 146)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Yoshikuni, Hattori, Nobutaka, Kondo, Tomoyoshi, Nomoto, Masahiro, Origasa, Hideki, Takahashi, Ryosuke, Yamamoto, Mitsutoshi, Yanagisawa, Nobuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610558/
https://www.ncbi.nlm.nih.gov/pubmed/28857772
http://dx.doi.org/10.1097/WNF.0000000000000239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610558/
https://www.ncbi.nlm.nih.gov/pubmed/28857772
http://dx.doi.org/10.1097/WNF.0000000000000239

Ejemplares similares